Mestre-Venice, October 25 th -26 th NH Laguna Palace Hotel Mestre, Venice

Similar documents
What s next in the antibiotic pipeline?

Course Coordinators. Course Objectives. Target Audience

2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania

2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania

Antibiotic treatment in the ICU 1. ICU Fellowship Training Radboudumc

International Meeting on Antimicrobial Chemotherapy in Clinical Practice (ACCP) October 16-19, 2003

OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS

INTERNATIONAL SYMPOSIUM ON ANTIMICROBIAL RESISTANCE

LINEE GUIDA: VALORI E LIMITI

Fighting MDR Pathogens in the ICU

Dr Eleri Davies. Consultant Microbiologist and Infection Control Doctor, Public Health Wales NHS Trust

Summary of the latest data on antibiotic consumption in the European Union

Le infezioni di cute e tessuti molli

Governance e sostenibilità nell antibioticoterapia. Anna Maria Cattelan UOC Malattie Infettive Azienda Ospedaliera Universitaria Padova

Antibiotic resistance: the rise of the superbugs

Maximizing Treatment Outcomes in an Era of Antibiotic Resistance

Healthcare Facilities and Healthcare Professionals. Public

High-Risk MDR clones news in treatment

«Antibiotic Stewardship» programmes & antibiotic resistance

Antimicrobial stewardship in managing septic patients

Summary of the latest data on antibiotic consumption in the European Union

A web-based interactive tool to explore antibiotic resistance and consumption via maps and charts

Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters

Quelle politique antibiotique pour l Europe? Dominique L. Monnet

Rational use of antibiotics

WHO laboratory-based global survey on multidrug-resistant organisms (MDROs) in health care interim analysis

Antimicrobial Cycling. Donald E Low University of Toronto

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011

Uso di antibiotici in ospedale: epidemiologia e misure di controllo

Introduction to antimicrobial resistance

Antibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco

Global Strategies to Address AMR Carmem Lúcia Pessoa-Silva, MD, PhD Antimicrobial Resistance Secretariat

Australia s response to the threat of antimicrobial resistance

Combating Drug-Resistant Infections Globally. Company Presentation

The role of carbapenems in the hospital

Antimicrobial Resistance Update for Community Health Services

Community-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018

Report on the APUA Educational Symposium: "Facing the Next Pandemic of Pan-resistant Gram-negative Bacilli"

Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017

Appropriate antimicrobial therapy in HAP: What does this mean?

What is the problem? Latest data on antibiotic resistance

Multidrug-resistant bacteria: what is the threat?

rates adjusted for age, sex, infection subclass, and type of antibiotic treatment used) by British Medical Journal Publishing Group

Antimicrobial resistance (EARS-Net)

Impact of Antimicrobial Resistance on Human Health. Robert Cunney HSE HCAI/AMR Programme and Temple Street Children s University Hospital

Overview of C. difficile infections. Kurt B. Stevenson, MD MPH Professor Division of Infectious Diseases

Antimicrobial consumption

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

Implementing Antibiotic Stewardship in Rural and Critical Access Hospitals

Preventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal

Combination vs Monotherapy for Gram Negative Septic Shock

How is Ireland performing on antibiotic prescribing?

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

by author ESCMID Online Lecture Library EUCAST The European Committee on Antimicrobial Susceptibility Testing September 2010

Antibiotic stewardship in long term care

Marco Tinelli. Giampiero Carosi

Responsible use of antibiotics

The UK 5-year AMR Strategy - a brief overview - Dr Berit Muller-Pebody National Infection Service Public Health England

Antibiotics R&D, B2B. Tentative Program. ***For available speaker slots*** conferenceseries.com. antibiotics.pharmaceuticalconferences.

Best Practices for Antimicrobial Stewardship Programs. October 25, :00 AM 5:00 PM New Orleans, LA Room:

7th International Course in PEDIATRIC AIRWAY: LIVE SURGERY, LECTURES, ALBATROSS CASES

Combating Antimicrobial Resistance: The Way Forward

New Opportunities for Microbiology Labs to Add Value to Antimicrobial Stewardship Programs

ESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano

Management of Nosocomial Infections in the Era of Increased Bacterial Resistance

Antimicrobial Stewardship Esperienza Torinese

ANTIMICROBIAL CONGRESS Amelioration in Research to Retried Antibiotics

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Using Web-Based Instruction Modules to Improve Practitioner Knowledge at Yale New Haven Hospital on the Prevention of Antimicrobial Resistance and

Successful stewardship in hospital settings

For analyst certification and disclosures please see page 7

Antimicrobial and Antibacterial Agents

The challenge of growing resistance

Antimicrobial stewardship

Taking Action to Prevent and Manage Multidrug-resistant Organisms and C. difficile in the Nursing Home: Part 1 Reviewing the organisms

OIE Reference Laboratory Reports Activities

Lefamulin: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM

These life-saving drugs have been a boon to medical care and benefited hundreds of million patients around the globe.

WHO s first global report on antibiotic resistance reveals serious, worldwide threat to public health

Health Service Executive Parkgate St. Business Centre, Dublin 8 Tel:

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS

7th International Course in PEDIATRIC AIRWAY: LIVE SURGERY, LECTURES, ALBATROSS CASES

Imagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening

PACK-CXL. for infectious keratitis. Farhad Hafezi, MD PhD. Professor of Ophthalmology Keck School of Medicine USC Los Angeles, USA

Antimicrobial Stewardship

Clostridium Difficile Infection (CDI) Alistair McGregor Hobart Pathology Royal Hobart Hospital TIPCU

Dr René A. Carlson President, World Veterinary Association. The Current and Future Role of the WVA in Continuing Education for Veterinarians

Bacterial infections complicating cirrhosis

Antimicrobial stewardship in companion animals: Welcome to a whole new era

Combating Drug-Resistant Infections Globally. Company Presentation

Antimicrobial Stewardship: The Premier Health Experience

Global response to antibiotic access and resistance: Stuart B. Levy, M.D. Tufts University School of Medicine Alliance for Prudent Use of Antibiotics

2016/LSIF/FOR/004 Policies to Promote Patient Access to Innovative Treatments and Combat Antimicrobial Resistance

Antimicrobial resistance and the need for stewardship. Dr Nick Brown RCP Acute Medicine conference, 16 April 2018

Multi-drug resistant microorganisms

NUOVE IPOTESI e MODELLI di STEWARDSHIP

Antimicrobial Resistance Initiative

MDRO s, Stewardship and Beyond. Linda R. Greene RN, MPS, CIC

Scottish Medicines Consortium

New Drugs for Bad Bugs- Statewide Antibiogram

Transcription:

3 rd edition Mestre-Venice, October 25 th -26 th 2018 NH Laguna Palace Hotel Mestre, Venice Chairman Matteo Bassetti (Italy) Co-Chairman David P. Nicolau (USA) International Scientific committee A. Brink (South Africa), T. Calandra (Switzerland), G. Dimopulos (Greece), C. Eckmann (Germany), R. Kozlov (Russia), P. Munoz (Spain), J.F. Timsit (France), M.V. Villegas (Colombia), M. Wilcox (UK) SCIENTIFIC PROGRAM Organized under the auspicies of Azienda Sanitaria Universitaria Integrata di Udine

3 rd edition SCIENTIFIC 08:30 08:45 Registration 08:45 09:00 Welcome and introduction - M. Bassetti (Italy) 09:00 10:40 Antimicrobial stewardship: can we do it better? Chair: S. Brusaferro (Italy), S. Stefani (Italy) 09:00 09:20 Bacteria and drugs now and in the next 30 years: who will be the winner? - G. Rossolini (Italy) 09:20 09:40 Impact of antimicrobial stewardship programs - A. Brink (South Africa) 09:40 10:00 How to develop a perfect program - E. Tacconelli (Italy) 10:00 10:20 Limitation of actual program of AMS and future directions - M.V. Villegas (Colombia) 10:20 10:40 Antifungal stewardship: how to do it? - E. Bouza (Spain) 10:40 11:00 Coffee Break 11:00 12:00 Recurrent C. difficile infection: kill the bug or cure the microbiome? Chair: F. Menichetti (Italy) 11:00 11:20 Introduction: C. difficile recurrence a disregarded medical challenge? - F. Menichetti (Italy) 11:20 11:40 Management of rec C. difficile infections: cure of symptoms or cure of the disease? - M. Wilcox (UK) 11:40 12:00 Prevention of C. difficile recurrence: evidence from a C. difficile antitoxin - E. Bouza (Spain) 12:00 13:00 Early adequate antibiotic therapy for MDR infections Chair: P.L. Viale (Italy), N. Petrosillo (Italy) 12:00 12:30 Managing serious Gram-positive infections appropriately - M. Dryden (UK) 12:30 13:00 Therapy of MDR/XDR Gram-negative bacteria: dealing with the evil - A. Soriano (Spain) 13:00 14:30 Lunch and poster walk with discussion

Mestre-Venice, October 25 th -26 th 2018 PROGRAM October 25 th 2018 14:30 15:00 An update in the management of community-acquired Pneumonia in an era of increasing antimicrobial resistance and antimicrobial stewardship - J. Garau (Spain) Chair: F. Blasi (Italy) 15:00 16:30 How to manage a septic patient in clinical practice Chair: C. Tascini (Italy), M. Venditti (Italy) 15:00 15:20 How to balance the need of the society and the need of the septic patient? - Y. Carmeli (Istrael) 15:20 15:40 Should we reduce mortality with an appropriate antibiotic treatment? - T. Calandra (Switzerland) 15:40 16:00 Are the new definition affecting the management of sepsis? - J. De Waele (Belgium) 16:00 16:20 Is the source control more important than antibiotics? - P. Montravers (France) 16:20 16:30 Discussion 16:30 17:00 Overview of antifungal strategies for severe mould infections - P. Munoz (Spain) Chair: L. Pagano (Italy) 17:00 18:30 Overview of next generation antibiotics Chair: D. Nicolau (USA), J. Garau (Spain) 17:00 17:30 New carbapenem combinations: - meropenem/vaborbactam - M. Bassetti (Italy) - imipenem/relebactam - A. Shorr (USA) - meropenem/nacubactam - M. Tumbarello (Italy) 17:30 17:40 Other betalactamase inhibitors combinations - D. Nicolau (USA) 17:40 17:50 Cefiderocol: a novel siderophore cephalosporin - P. L. Viale (Italy) 17:50 18:00 Eravacycline: a novel fluorocycline developed for the treatment of ciai - M. Bassetti (Italy) 18:00 18:10 Omadacycline: a novel tetracycline subclass antibiotics - P. Montravers (France) 18:10 18:20 Delafloxacin: a novel fluoroquinolone antibiotic - J. Garau (Spain) 18:20 18:30 Lefamulin: a novel pleuromutilin antibiotic class - G. Dimopoulos (Greece)

3 rd edition SCIENTIFIC 08:30 10:15 Critically ill patients and difficult to treat bugs: a challenging scenario Chair: M. Girardis (Italy), F. De Rosa (Italy) 08:30 08:45 The eternal dilemma for non-fermenters: monotherapy or combination? - T. Calandra (Switzerland) 08:45 09:00 Optimization of PK/PD of antibiotics for resistant Gram-negative organisms - F. Pea (Italy) 09:00 09:15 A.baumannii js just a bad marker for prognosis or a real killer? - M. Akova (Turkey) 09:15 09:30 CRE can we define a universal strategic treatment management? - D. Nicolau (USA) 09:30 09:45 Serious MRSA infection: anything new? - M. Wilcox (UK) 09:45 10:00 Any role for old antibiotics? - G. Dimopoulos (Greece) 10:00 10:15 When do we need to treat Candida empirically? - J.F. Timsit (France) 10:15 10:30 Coffee Break 10:30 12:00 New directions and evidences in the management of complicated skin and skin structure infections Chair: F. Menichetti (Italy), C. Eckmann (Germany) 10:30 10:50 How to stratify the risk of MDR in cssti and how to be appropriate - A. Shorr (USA) 10:50 11:10 Novel therapeutic approaches for cssti - M. Dryden (UK) 11:10 11:30 The role of long acting antibiotics - A. Soriano (Spain) 11:30 11:50 The role of new fluoroquinolones - C. Eckmann (Germany) 11:50 12:00 Discussion 12:00 13:00 Main Consideration for Recognizing and Best Managing Patients with Critical Pseudomonal Infections Chair: M. Bassetti (Italy) 12:00 12:30 Difficult to treat Gram(-) infections: implication of epidemiology and local ecology data to treatment strategies - J.F. Timsit (France) 12:30 13:00 Latest evidence and guidelines on new antibiotics - What antibiotic for which patient? - M. Bassetti (Italy) 13:00 14:30 Lunch and poster walk with discussion

Mestre-Venice, October 25 th -26 th 2018 PROGRAM October 26 th 2018 14:30 15:30 Rezafungin: a novel echinocandin for Treatment and Prevention of IFI Chair: M. Bassetti (Italy) 14:30 15:00 Prevention and management of fungal infections: we can do better - R. Lewis (Italy) 15:00 15:30 New options for prevention & treatment of IFI - T. Sandison (USA) 15:30 17:00 New and rapid diagnostic methods Chair: G. Rossolini (Italy) 15:30 16:00 New diagnostic methods for fungal infections - M. Sanguinetti (Italy) 16:00 16:30 New diagnostic methods for hepatitis - S. Chevaliez (France) 16:30 17:00 New diagnostic methods for early identification of bacteria - D. Nicolau (USA) 17:00 17:30 Final test and conclusions

Scientific Secretariat Professor Matteo Bassetti, MD PhD Head, Infectious Diseases Clinic Univesity of Udine and Santa Maria Misericordia University Hospital Udine - Italy Tel +39 0432.559353 Fax +39 0432.559360 matteo.bassetti@asuiud.sanita.fvg.it Congress Venue Hotel NH Laguna Palace Viale Ancona, 2 30172 Mestre, Venice Italy CME Accreditation The Conference was granted 9,8 CME creditis by Age.Na.S. for the following specialities: BIOLOGO INFERMIERE FARMACISTA OSPEDALIERO MEDICO CHIRURGO specialista in: Anestesia e Rianimazione; Chirurgia Generale; Dermatologia e Venereologia; Ematologia; Epidemiologia; Farmacologia e Tossicologia Clinica; Gastroenterologia; Malattie dell apparato Respiratorio; Malattie Infettive; Medicina Interna; Microbiologia e Virologia; Nefrologia; Oncologia. Organizing Secretariat Academy srl via Aosta 4/A 20155 Milan-Italy Tel. +39 02.87063370 Fax +39 02.92853286 info@academy-congressi.it luigi.parravicini@academy-congressi.it